文献速递慢性静脉疾病

使用可注射聚多卡醇静脉内微泡沫(Varithena)行大隐静脉消融术后抗血栓策略的前瞻性随机试验

Prospective randomized trial of antithrombotic strategies following great saphenous vein ablation using injectable polidocanol endovenous microfoam (Varithena).
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-12-31

前瞻性随机试验纳入257例患者304条肢体,比较单纯压迫、压迫加深静脉系统盐水冲洗、压迫加冲洗加阿哌沙班5天三种策略对消融后浅表血栓延伸和深静脉血栓的影响。阿哌沙班组DVT发生率1.98%,显著低于单纯压迫组16.7%和冲洗组14.7%;冲洗对DVT无影响,各组浅表血栓延伸均低。

要点

  • 大隐静脉聚多卡醇微泡沫消融术后,加用阿哌沙班5天可显著降低DVT发生率至1.98%。
  • 深静脉系统盐水冲洗对DVT发生率无影响,冲洗组14.7%与单纯压迫组16.7%无统计学差异。
  • 浅表血栓延伸在各组均低(0%-1%),加用冲洗或抗凝未进一步降低。

核心结论

  • 加用深静脉系统冲洗或抗凝均未降低临床相关的隐股交界浅表血栓延伸(II-IV级)发生率,各组均低(0%-1%),显著低于既往报告的2.3%-4.1%。
  • 深静脉系统冲洗对DVT发生率无影响;单纯压迫或压迫加冲洗时观察到的PEM所致DVT发生率(分别为16.7%和14.7%)显著高于既往报告的2.5%-9.6%,可能与本研究治疗的大隐静脉属支范围更大有关。
  • 术后口服阿哌沙班5 mg每日两次共5天,显著降低DVT发生率至1.98%,与未抗凝患者的16.7%相比。
  • 术后阿哌沙班抗凝可能在降低PEM消融后DVT发生中具有显著预防作用。

研究设计与样本

  • 前瞻性随机试验,纳入257例患者共304条肢体,接受Varithena 1%聚多卡醇静脉内微泡沫消融。
  • 患者随机分为三组:单纯隐股交界压迫(C组,103条肢体,33.8%)、压迫加深静脉系统盐水冲洗(D组,101条肢体,32.9%)、压迫加冲洗加术后口服阿哌沙班5 mg每日两次共5天(A组,100条肢体,33.2%)。
  • 消融术后7至10天行双功超声检查,比较各组浅表血栓延伸和DVT发生率(主要终点)。

主要发现

  • 平均超声随访时间9.7天(全部患者),大隐静脉主要闭合率92.4%。
  • 隐股交界浅表血栓延伸(II-IV级)发生率:C组0.9%、D组1.0%、A组0%。
  • DVT发生率:C组16.7%、D组14.7%、A组1.98%(χ2检验,P = .002)。
  • A组与C组比较,DVT发生率1.98% vs 16.7%(χ2检验,P < .001);A组与D组比较,1.98% vs 14.7%(χ2检验,P = .00162);C组与D组比较,16.7% vs 14.7%(χ2检验,P = .60),无统计学差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Postablation deep vein thrombosis (DVT) represents a potentially serious complication after Varithena polidocanol endovenous microfoam (PEM) ablation. The following primary outcomes were assessed: whether (1) adjunctive apixaban anticoagulation or (2) mechanical deep venous system (DVS) saline flushing could decrease saphenofemoral junction (SFJ) thrombus extension (postablation superficial thrombus extension [PASTE]) and/or DVT compared with compression alone, after great saphenous vein (GSV) PEM ablation. METHODS: Varithena 1% PEM ablation patients were randomized to (1) SFJ compression, (2) compression and DVS saline flushing, or (3) compression, DVS saline flushing, and 5 days of postprocedural 5 mg oral apixaban anticoagulation twice daily. Duplex imaging was obtained 7 to 10 days after PEM ablation and PASTE/DVT incidence (primary end point) was compared between groups at this time point. RESULTS: We treated 304 limbs in 257 patients with PEM. Overall, 103 limbs received SFJ compression (group C, 33.8%), 101 received compression and deep venous flushing (group D, 32.9%), and 100 received compression, deep flush, and anticoagulation (group A, 33.2%). Mean ultrasound follow-up time was 9.7 days (all patients) with a primary GSV closure rate of 92.4%. SFJ PASTE (II-IV) occurred in 0.9%, 1.0%, and 0% (groups C, D, and A, respectively). DVT occurred in 16.7%, 14.7%, and 1.98% (groups C, D, and A; χ2, P = .002). Patients in group A receiving apixaban anticoagulation had a significant reduction in DVT compared with patients in group C (1.98% vs 16.7%, χ2; P < .001); likewise, patients in group A had a significantly decreased DVT occurrence compared with group D (14.7% vs 1.98%; χ2, P = .00162), whereas patients in groups C and D were not statistically different (16.7% vs 14.7%; χ2, P = .60). CONCLUSIONS: (1) Neither adjunctive DVS flushing nor anticoagulation decreased clinically relevant SFJ PASTE (II-IV) incidence, which remained similarly low across all groups and ranged between 0% and 1%, regardless of adjunctive DVS flushing or anticoagulation. This rate was significantly lower than prior reports (2.3%-4.1%). (2) DVS flushing had no influence on the rate of DVT. Observed PEM-induced DVT incidence using SFJ compression alone or compression with DVS flushing (16.7% and 14.7%, respectively) was significantly higher than prior reports (2.5%-9.6%). This finding may relate to the greater extent of AK/BK GSV territory treated in the present study. (3) Five days of postprocedural oral apixaban anticoagulation, 5 mg given twice daily, significantly decreased DVT occurrence to 1.98%, compared with nonanticoagulated patients (16.7%). This finding is comparable with the DVT rates reported after endovenous thermal ablation (0.7-1.7%). (4) Postprocedural apixaban anticoagulation may have a significant preventive role in decreasing DVT occurrence after PEM ablation.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Yang J, Chung S, Srivatsa S, et al. Prospective randomized trial of antithrombotic strategies following great saphenous vein ablation using injectable polidocanol endovenous microfoam (Varithena). J Vasc Surg Venous Lymphat Disord. 2022. PMID: 36592692. doi:10.1016/j.jvsv.2022.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。